Genome-wide association study of treatment-related toxicity two years following radiotherapy for breast cancer.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
10 2023
Historique:
received: 20 03 2023
revised: 04 07 2023
accepted: 06 07 2023
medline: 15 9 2023
pubmed: 13 7 2023
entrez: 12 7 2023
Statut: ppublish

Résumé

Up to a quarter of breast cancer patients treated by surgery and radiotherapy experience clinically significant toxicity. If patients at high risk of adverse effects could be identified at diagnosis, their treatment could be tailored accordingly. This study was designed to identify common single nucleotide polymorphisms (SNPs) associated with toxicity two years following whole breast radiotherapy. A genome-wide association study (GWAS) was performed in 1,640 breast cancer patients with complete SNP, clinical, treatment and toxicity data, recruited across 18 European and US centres into the prospective REQUITE cohort study. Toxicity data (CTCAE v4.0) were collected at baseline, end of radiotherapy, and annual follow-up. A total of 7,097,340 SNPs were tested for association with the residuals of toxicity endpoints, adjusted for clinical, treatment co-variates and population substructure. Quantile-quantile plots showed more associations with toxicity above the p < 5 × 10 This GWAS for long-term breast radiation toxicity provides further evidence for significant association of common SNPs with distinct toxicity endpoints.

Sections du résumé

BACKGROUND AND PURPOSE
Up to a quarter of breast cancer patients treated by surgery and radiotherapy experience clinically significant toxicity. If patients at high risk of adverse effects could be identified at diagnosis, their treatment could be tailored accordingly. This study was designed to identify common single nucleotide polymorphisms (SNPs) associated with toxicity two years following whole breast radiotherapy.
MATERIALS AND METHODS
A genome-wide association study (GWAS) was performed in 1,640 breast cancer patients with complete SNP, clinical, treatment and toxicity data, recruited across 18 European and US centres into the prospective REQUITE cohort study. Toxicity data (CTCAE v4.0) were collected at baseline, end of radiotherapy, and annual follow-up. A total of 7,097,340 SNPs were tested for association with the residuals of toxicity endpoints, adjusted for clinical, treatment co-variates and population substructure.
RESULTS
Quantile-quantile plots showed more associations with toxicity above the p < 5 × 10
CONCLUSIONS
This GWAS for long-term breast radiation toxicity provides further evidence for significant association of common SNPs with distinct toxicity endpoints.

Identifiants

pubmed: 37437607
pii: S0167-8140(23)00344-4
doi: 10.1016/j.radonc.2023.109806
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109806

Subventions

Organisme : Wellcome Trust
ID : 218505/Z/19/Z
Pays : United Kingdom
Organisme : Department of Health
ID : CL 2017-11-002
Pays : United Kingdom
Organisme : Department of Health
ID : DRF 2014-07-079
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C1094/A1850
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C147/A25254
Pays : United Kingdom

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Harkeran K Jandu (HK)

Department of Genetics and Genome Biology, University of Leicester, Leicester, United Kingdom.

Colin D Veal (CD)

Department of Genetics and Genome Biology, University of Leicester, Leicester, United Kingdom.

Laura Fachal (L)

Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.

Craig Luccarini (C)

Centre for Cancer Genetic Epidemiology, Strangeways Research Laboratory, University of Cambridge, Cambridge, United Kingdom.

Miguel E Aguado-Barrera (ME)

Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain; Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain.

Manuel Altabas (M)

Department of Radiation Oncology, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.

David Azria (D)

Institut de Recherche en Cancérologie de Montpellier, University Federation of Radiation Oncology of Mediterranean Occitanie, Université de Montpellier, INSERM U1194 IRCM, Montpellier, France.

Adinda Baten (A)

Radiation Oncology, UZ Leuven, Leuven, Belgium.

Celine Bourgier (C)

Institut de Recherche en Cancérologie de Montpellier, University Federation of Radiation Oncology of Mediterranean Occitanie, Université de Montpellier, INSERM U1194 IRCM, Montpellier, France.

Renée Bultijnck (R)

Department of Human Structure and Repair, Ghent University, Ghent, Belgium.

Riccardo R Colciago (RR)

Unit of Radiation Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Marie-Pierre Farcy-Jacquet (MP)

Institut de Cancérologie du Gard, University Federation of Radiation Oncology of Mediterranean Occitanie, CHU Carémeau, Nîmes, France.

Jenny Chang-Claude (J)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Cancer Epidemiology Group, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Ananya Choudhury (A)

Translational Radiobiology Group, Division of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Christie Hospital, Manchester, UK.

Alison Dunning (A)

Centre for Cancer Genetic Epidemiology, Strangeways Research Laboratory, University of Cambridge, Cambridge, United Kingdom.

Rebecca M Elliott (RM)

Translational Radiobiology Group, Division of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Christie Hospital, Manchester, UK.

Sheryl Green (S)

Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Sara Gutiérrez-Enríquez (S)

Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.

Carsten Herskind (C)

Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.

Maarten Lambrecht (M)

Radiation Oncology, UZ Leuven, Leuven, Belgium.

Christel Monten (C)

Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium.

Tiziana Rancati (T)

Unit of Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Victoria Reyes (V)

Department of Radiation Oncology, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.

Barry S Rosenstein (BS)

Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Dirk De Ruysscher (D)

MAASTRO Clinic, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, Netherlands.

Maria Carmen De Santis (M)

Unit of Radiation Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Petra Seibold (P)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Elena Sperk (E)

Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.

Marlon Veldwijk (M)

Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.

R Paul Symonds (R)

Leicester Cancer Research Centre, University of Leicester, Leicester, United Kingdom.

Hilary Stobart (H)

Patient Advocate, Independent Cancer Patients' Voice, UK.

Begoña Taboada-Valladares (B)

Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain; Department of Radiation Oncology, Complexo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain.

Ana Vega (A)

Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain; Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain.

Liv Veldeman (L)

Department of Human Structure and Repair, Ghent University, Ghent, Belgium; Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium.

Adam J Webb (AJ)

Department of Genetics and Genome Biology, University of Leicester, Leicester, United Kingdom.

Caroline Weltens (C)

Radiation Oncology, UZ Leuven, Leuven, Belgium.

Catharine M West (CM)

Translational Radiobiology Group, Division of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Christie Hospital, Manchester, UK.

Tim Rattay (T)

Leicester Cancer Research Centre, University of Leicester, Leicester, United Kingdom. Electronic address: tr104@le.ac.uk.

Christopher J Talbot (CJ)

Department of Genetics and Genome Biology, University of Leicester, Leicester, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH